Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Given Alone, With IL-12 DNA, or With a Dose Escalation of IL-15 DNA, in Healthy, HIV-1-uninfected Adults Participants
Conditions
Interventions
PennVax B
IL-12
+1 more
Locations
8
United States
Alabama Vaccine CRS
Birmingham, Alabama, United States
San Francisco Vaccine and Prevention CRS
San Francisco, California, United States
Brigham and Women's Hosp. CRS
Boston, Massachusetts, United States
NY Blood Ctr./Union Square CRS
New York, New York, United States
HIV Prevention & Treatment CRS
New York, New York, United States
NY Blood Ctr./Bronx CRS
The Bronx, New York, United States
Start Date
October 1, 2007
Primary Completion Date
January 1, 2010
Completion Date
January 1, 2010
Last Updated
October 14, 2021
NCT06627764
NCT04142047
NCT06694805
NCT07428330
NCT05398185
NCT07225530
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions